Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at Cantor Fitzgerald

Analysts at Cantor Fitzgerald began coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a note issued to investors on Friday,Benzinga reports. The brokerage set an “overweight” rating on the stock.

ACRV has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. BMO Capital Markets dropped their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Finally, KeyCorp initiated coverage on Acrivon Therapeutics in a research report on Friday. They issued an “overweight” rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Stock Up 4.8 %

Shares of Acrivon Therapeutics stock opened at $6.07 on Friday. Acrivon Therapeutics has a 12-month low of $3.19 and a 12-month high of $11.90. The company has a market capitalization of $189.02 million, a price-to-earnings ratio of -2.25 and a beta of 0.77. The firm’s 50-day moving average price is $6.34 and its two-hundred day moving average price is $7.34.

Institutional Investors Weigh In On Acrivon Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Exome Asset Management LLC bought a new stake in Acrivon Therapeutics in the third quarter valued at approximately $817,000. State Street Corp boosted its stake in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after purchasing an additional 47,233 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after buying an additional 28,748 shares during the period. Barclays PLC raised its stake in Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after buying an additional 11,273 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Acrivon Therapeutics in the second quarter valued at $58,000. 71.62% of the stock is owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.